Updated:
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals traces its origins to 1989, though its modern identity and exclusive focus on RNA interference therapeutics crystallized after...
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals traces its origins to 1989, though its modern identity and exclusive focus on RNA interference therapeutics crystallized after Christopher Anzalone became CEO in 2007. The company relocated its headquarters from Madison, Wisconsin to Pasadena, California, where it now operates the bulk of its research and development. Its scientific foundation rests on a proprietary Targeted RNAi Molecule platform designed to precisely silence the production of specific proteins driving disease. The company's pipeline strategy centers on developing both wholly owned and partnered drug candidates, with a particular concentration in cardiometabolic, pulmonary, and neuromuscular disorders. In February 2024, Amgen made a $500 million equity investment in the company as part of a broader cardiovascular collaboration, and later in October 2024, Royalty Pharma invested $550 million alongside a co-development deal for plozasiran, Arrowhead's lead cardiometabolic candidate. The firm operates a second major research facility in Madison, Wisconsin, and its development reach extends through partnerships across the United States, Europe, and Japan, including a major liver disease collaboration with GSK. Anzalone leads a workforce of several hundred scientists and professionals, managing a pipeline that balances partnered programs generating milestone and royalty revenue against self-funded wholly owned assets. In May 2024, the firm reported positive Phase 2 data for its investigational RNAi therapy ARO-RAGE in asthma, demonstrating significant reductions in fractional exhaled nitric oxide, a key marker of lung inflammation. The company's financial architecture relies on periodic large-scale partnership deals rather than traditional AUM, with the Amgen and Royalty Pharma transactions providing multi-year cash runways. Arrowhead's structural differentiator lies in its TRiM platform's ability to target multiple tissue types — a technical breadth that many peer RNAi companies lack. While competitors like Alnylam concentrated for years on liver-targeted delivery, Arrowhead moved aggressively into extra-hepatic tissues including lung and muscle, creating a pipeline of first-in-class opportunities that attracted deep-pocketed partners seeking platform-wide access rather than single-asset bets.
General information
Firm type
Asset Manager
Year founded
1989
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Pasadena
Corporate office
Pasadena, CA, United States
Additional offices
Madison, WI, United States
Principals
Christopher Anzalone
President and CEO
James Hassard
Chief Commercial Officer
Sector focus
Frequently asked questions
Who runs research and development decisions at Arrowhead?
President and CEO Christopher Anzalone has led Arrowhead since 2007, steering its strategic pivot to RNAi therapeutics. He oversees the executive team that manages the pipeline, though the firm publicly credits its broader scientific leadership for individual program decisions. Day-to-day R&D operations are conducted from the Pasadena headquarters and the Madison research facility.
How does Arrowhead fund its operations without a traditional AUM?
Arrowhead is a clinical-stage biotechnology company, not an investment fund. It finances its operations through equity offerings, debt, and large-scale licensing and co-development partnerships with pharmaceutical companies. The $500 million Amgen investment and $550 million Royalty Pharma commitment in 2024 serve as recent examples of this non-dilutive and equity-linked funding model (per the firm, 2024).
What is Arrowhead's relationship with Amgen and Royalty Pharma?
In 2024, Arrowhead entered into two separate, significant transactions. Amgen made a $500 million equity investment as part of a cardiovascular collaboration. Royalty Pharma committed $550 million upfront in a co-development deal for plozasiran, Arrowhead's investigational therapy for familial chylomicronemia syndrome, in exchange for a royalty on future sales (per the firm, October 2024).
Which therapeutic areas does Arrowhead target beyond cardiovascular disease?
Arrowhead's pipeline extends into pulmonary, neuromuscular, and liver disease. It has wholly owned pulmonary programs, including ARO-RAGE for asthma, which reported positive Phase 2 data in 2024. The firm also maintains a liver disease partnership with GSK, applying its TRiM platform to conditions requiring hepatic gene silencing (per the firm's pipeline disclosures).
How is Arrowhead's RNAi technology distinct from competitors like Alnylam?
Arrowhead's TRiM platform is engineered to deliver siRNA molecules to multiple tissue types, including liver, lung, and muscle. This contrasts with some earlier RNAi platforms that primarily achieved effective liver delivery. Arrowhead has used this extra-hepatic targeting capability to build a pipeline of first-in-class programs in diseases where genetic targets exist outside the liver.
What is plozasiran and why is it central to Arrowhead's value proposition?
Plozasiran is Arrowhead's lead investigational RNAi therapeutic, designed to reduce triglycerides and the risk of acute pancreatitis in patients with familial chylomicronemia syndrome. The Royalty Pharma agreement in 2024 underscored its value, providing a large upfront payment and tying future returns to the drug's commercial success. It is a key validation point for the firm's cardiovascular pipeline.
Does Arrowhead license its TRiM platform technology to other companies?
Arrowhead historically engaged in platform licensing deals, most notably a broad collaboration with Amgen to develop multiple RNAi candidates. These arrangements provide upfront cash and milestone payments. Current partnerships with GSK and the Royalty Pharma co-development deal represent the evolution of this strategy from pure licensing into shared development and royalty-based structures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: